Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...
WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...
The initial choice of an oral nonbiologic systemic therapy for patients with psoriasis is often driven by insurance requirements; patients often must try and fail treatment with an older therapy ...
Please provide your email address to receive an email when new articles are posted on . Tremfya (guselkumab) is an interleukin-23 inhibitor. The submissions are supported by clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results